Literature DB >> 15213322

Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.

Andreas Fusshoeller1, Marcus Plail, Bernd Grabensee, Joerg Plum.   

Abstract

BACKGROUND: In chronic ambulatory peritoneal dialysis, bicarbonate-buffered fluids, with their neutral pH and less advanced glycosylation end-products (AGE) and glucose degradation products (GDP), have better biocompatibility than conventional peritoneal dialysis (PD) solutions. That difference may be more beneficial in automated peritoneal dialysis (APD), due to its more frequent exchanges and longer contact times with fresh dialysate. We performed a prospective, randomized study in APD patients to compare the biocompatibility of conventional and bicarbonate/lactate-buffered PD fluids.
METHODS: We randomized 14 APD patients to have APD with either conventional or bicarbonate/lactate-based fluids. After 6 months, both groups changed to the other solution. The overall observation period was 12 months. After 1 and 5 months and again after 7 and 11 months, phagocytotic and respiratory burst capacities of effluent peritoneal macrophages were determined. Plasma interleukin (IL)-6 and C-reactive protein (CRP) as well as effluent IL-6, CRP, transforming growth factor (TGF)-beta 1, AGE and CA125 concentrations were measured. Inflow pain was quantified using a patient questionnaire.
RESULTS: Respiratory burst capacity remained unchanged and phagocytotic activity increased significantly during APD (P<0.001) with the bicarbonate/lactate fluid. Effluent IL-6 release was significantly lower than with the lactate fluid (P<0.05). While in the effluent TGF-beta 1 was unaffected, AGE concentration was lower after bicarbonate/lactate treatment (P<0.05). Effluent CA125 concentration, an indicator of mesothelial cell integrity, was higher (P<0.05) in neutral effluents. Finally, patients' inflow pain diminished (P = 0.05) when using the neutral fluid.
CONCLUSIONS: The use of a neutral PD fluid in APD improved patients' inflow pain as well as biocompatibility parameters reflecting enhanced phagocytotic activity of peritoneal macrophages, reduced constitutive inflammatory stimulation (IL-6), reduced AGE accumulation in the peritoneal cavity and better preservation of the mesothelial cell integrity. From the biocompatibility point of view, a neutral fluid with low GDP content can be recommended as the primary choice for APD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213322     DOI: 10.1093/ndt/gfh326

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

1.  Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.

Authors:  Cengiz Candan; Pınar Turhan; Lale Sever; Mahmut Civilibal; Nur Canpolat; Salim Caliskan; Ozgur Kasapcopur; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2011-01-29       Impact factor: 3.714

2.  Predictive model for delayed graft function based on easily available pre-renal transplant variables.

Authors:  Gianluigi Zaza; Pietro Manuel Ferraro; Gianpaolo Tessari; Silvio Sandrini; Maria Piera Scolari; Irene Capelli; Enrico Minetti; Loreto Gesualdo; Giampiero Girolomoni; Giovanni Gambaro; Antonio Lupo; Luigino Boschiero
Journal:  Intern Emerg Med       Date:  2014-08-28       Impact factor: 3.397

Review 3.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

4.  A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.

Authors:  Kar Neng Lai; Man Fai Lam; Joseph C K Leung; Loretta Y Chan; Christopher W K Lam; Iris H S Chan; Hoi Wong Chan; Chun Sang Li; Sunny S H Wong; Yiu Wing Ho; Au Cheuk; Matthew K L Tong; Sydney C W Tang
Journal:  Perit Dial Int       Date:  2011-11-03       Impact factor: 1.756

5.  Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.

Authors:  Tatiana De Los Ríos; Juan Pérez-Martínez; Jose Portoles; Monika Lichodziejewska-Niemierko; Maite Rivera; Michał Nowicki; Andrzej Książek; Ana María Tato; Christine Bohnhorst; Mariano Feriani
Journal:  Perit Dial Int       Date:  2016 9-10       Impact factor: 1.756

Review 6.  Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis.

Authors:  Andreas Fusshoeller
Journal:  Pediatr Nephrol       Date:  2007-07-19       Impact factor: 3.714

Review 7.  Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  Harpaul Cheema; Joanne M Bargman
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

Review 8.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

9.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28

10.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.